ライフサイエンスコーパス: prostaglandin E2

1 ssed cyclooxygenase 1/2 and basally secreted prostaglandin E2.

2 key modulator of inflammation and immunity, prostaglandin E2.

3 oduction/release of TNF-alpha, IL-1beta, and prostaglandin E2.

4 inflammatory factors, including TGF-beta and prostaglandin E2.

5 mpaired levels of cysteinyl-leukotrienes and prostaglandin E2.

6 ction of proinflammatory effectors including prostaglandin E2.

7 h cyclooxygenase (COX)-2 in the synthesis of prostaglandin E2.

8 ajor histocompatibility complex class II and prostaglandin E2.

9 rleukin-1ra, keratinocyte growth factor, and prostaglandin E2.

10 were observed for IL-1alpha, MIP-1alpha, and prostaglandin E2.

11 rly induces the beta-catenin pathway through prostaglandin E2.

12 the biosynthesis of prostacyclin (PGI2) and prostaglandin E2.

13 nd the cyclooxygenase-associated metabolites prostaglandin E2, 11-hydroxyeicosatetraenoic acid, and t

14 (HCC) growth by 15-PGDH through the 15-keto-prostaglandin E2 (15-keto-PGE2)/peroxisome proliferator-

15 Although suppression of prostaglandin E2 accounts for the protective effect of m

16 PPARgamma) activator rosiglitazone (Rosi) or prostaglandin E2 analog (16,16-dimethyl PGE2) to adipose

17 Aqueous and vitreous levels of prostaglandin E2 and 16 other inflammatory cytokines imp

18 Prostaglandin E2 and bradykinin can activate airway sens

19 n were performed and included measurement of prostaglandin E2 and cytosolic phospholipase A2 activity

20 isruption of the protein's ability to induce prostaglandin E2 and cytosolic phospholipase A2 synthesi

21 sident peritoneal macrophages, prostacyclin, prostaglandin E2 and leukotriene C4 were produced within

22 portantly, we discovered that Galphaq-linked prostaglandin E2 and leukotriene D4 receptors also regul

23 demonstrated increased urinary excretion of prostaglandin E2 and metabolites.

24 tantly, MKO(GFAP) mice exhibit reduced brain prostaglandin E2 and pro-inflammatory cytokine levels up

25 tion initiating mediators leukotriene B4 and prostaglandin E2 and pro-resolving mediators resolvin D1

26 1 sensitization to the inflammatory mediator prostaglandin E2 and the chemotherapeutic drug oxaliplat

27 Prostaglandin E2 and thromboxane A2, as well as total AP

28 nalogues, and the cyclooxygenase metabolites prostaglandin E2 and thromboxane B2 differed at baseline

29 Because prostaglandin E2 and tumor necrosis factor-alpha are als

30 ammatory lipid mediators, Leukotriene B4 and Prostaglandin E2, and a concomitant decrease of resolvin

31 n explants were stimulated with IL-1beta and prostaglandin E2, and their effects on the release of CO

32 lammatory lipid mediators leukotriene B4 and prostaglandin E2 are elevated in the chronic spinal cord

33 We show that COX-2 and prostaglandin E2 are required for C1P-mediated increases

34 evelopmentally regulated by the inflammatory prostaglandin E2, but in different ways.

35 accelerate thrombogenesis, while suppressing prostaglandin E2, but increasing biosynthesis of PGI2.

36 Dilation is mediated by prostaglandin E2, but requires nitric oxide release to s

37 ia-synapse cross talk requires production of prostaglandin E2 by microglia, leading to the activation

38 dsRNA-induced WIHN and Wnt7b, and exogenous prostaglandin E2 can rescue WIHN and Wnt7b.

39 inhibited mechanical hyperalgesia induced by prostaglandin E2, carrageenan-induced hyperalgesia, and

40 ponses to capsaicin but reduced responses to prostaglandin E2 compared with healthy volunteers.

41 e with the loss of the antifibrotic mediator prostaglandin E2 contributes to the fibrotic process in

42 Both AREG and prostaglandin E2 converge to activate signaling through

43 The inflammatory cyclooxygenase/prostaglandin E2 (COX/PGE2) pathway has been implicated

44 otriene B4 , 11-dehydro-thromboxane B2 , and prostaglandins E2 , D2 , and F2alpha and their metabolit

45 16,16-Dimethyl prostaglandin E2 (dmPGE2) was previously identified to b

46 of hematopoietic grafts with 16-16 dimethyl prostaglandin E2 (dmPGE2).

47 pressed biosynthesis of prostaglandin I2 and prostaglandin E2, elevated blood pressure, and accelerat

48 izes prostanoid prostaglandin D2 (DP)1, DP2, prostaglandin E2 (EP)1, EP4, prostaglandin F2alpha, and

49 Prostaglandin E2 , EP2 agonists and EP4 agonists inhibit

50 with cardiomyocyte-selective knockout of the prostaglandin E2 EP4 receptor sub-type (EP4 KO) exhibit

51 The prostaglandin E2/EP4 agonist also stimulated MMP-9 expre

52 induced by diverse pronociceptive mediators, prostaglandin E2, epinephrine, TNFalpha, and interleukin

53 eased medullary COX-2 expression and urinary prostaglandin E2 excretion and developed salt-sensitive

54 , increased free water reabsorption, urinary prostaglandin E2 excretion, and reduced excretion of ser

55 sociated with PGD, four of which were in the prostaglandin E2 family of genes.

56 UV-induced prostaglandin E2 has been implicated as an intermediary

57 The role of prostaglandin E2 in immune regulation has been better de

58 egulated increase in expression of Cox-2 and prostaglandin E2 in MDSCs in mediating this effect.

59 Prostaglandin E2 increased in controls and EPI group and

60 As a positive control, serosal 1 muM prostaglandin E2 increased mucin release to ~400% of the

61 Elevation of baseline urinary metabolite of prostaglandin E2, indicating activation of the COX-2 pat

62 monstrate that paracrine signaling involving prostaglandin E2-induced cAMP generation has the potenti

63 terminal to mediate a marked prolongation of prostaglandin E2-induced hyperalgesia.

64 obesity-associated and tumor-derived factor prostaglandin E2, inhibits p53 in the breast adipose str

65 on of cultured small-diameter DRG neurons by prostaglandin E2 is also prevented and reversed by HMWH.

66 In other tissues, prostaglandin E2 is an important effector of regeneratio

67 Prostaglandin E2 is now widely recognized to play critic

68 Functionally, aortic Leukotriene B4 and Prostaglandin E2 levels correlated with traits of plaque

69 with clinically approved drugs that augment prostaglandin E2 levels in these settings prevented acut

70 Plaa-null mice were generated and prostaglandin E2 levels were measured in different tissu

71 Urinary metabolite of prostaglandin E2 may be able to identify patients who co

72 phorylation of PREX1 after isoproterenol and prostaglandin E2-mediated GPCR activation is partially P

73 d potently mitigate experimental colitis via prostaglandin E2-mediated immunosuppression.

74 oncentrations counterregulated adenosine and prostaglandin E2-mediated inhibition of ERK1/2 activatio

75 omponents, the enantioselective synthesis of prostaglandin E2 methyl ester has been achieved through

76 Inflammatory mediators such as prostaglandin-E2 or bradykinin cause hyperalgesia by act

77 etoricoxib on urinary excretion of tetranor-prostaglandin E2 (P < .001).

78 h and bone density (P <0.01), enhanced 7-day prostaglandin E2 (P <0.01), and reduced 28-day inflammat

79 and elevated levels of its enzymatic product prostaglandin E2 (PGE(2)) occur in the majority of color

80 tion of the Galphas-coupled EP2 receptor for prostaglandin E2 (PGE(2)) promotes cell survival in seve

81 We found that the prostaglandin E2 (PGE(2)) receptors EP2 and EP4 were upr

82 h increased levels of interleukin (IL)-6 and prostaglandin E2 (PGE(2)), 2 inflammatory mediators know

83 Decreased COX-2 was accompanied by reduced prostaglandin E2 (PGE(2)), a major prostanoid produced d

84 Nitric oxide (NO) and prostaglandin E2 (PGE(2)), downstream products, were als

85 We determined vitreous levels of prostaglandin E2 (PGE(2)), VEGF, and 15 other cytokines

86 flammatory mediators including cytokines and prostaglandin E2 (PGE(2)), with limited side effects ass

87 expression elicited by low-dose forskolin or Prostaglandin E2 (PGE(2)).

88 btypes whose cognate physiological ligand is prostaglandin-E2 (PGE(2)).

89 Prostaglandin E2 (PGE2 ) has been shown to inhibit IgE-d

90 enase-2 (COX-2) and its prostanoid products, prostaglandin E2 (PGE2 ) in particular, are key contribu

91 89 +/- 17.47 pg/mg protein; P <0.05); and 3) prostaglandin E2 (PGE2) (LPS: 159.20 +/- 38.70 pg/mg wet

92 We found that prostaglandin E2 (PGE2) accumulates in the CM in a time-

93 The two synthetic pathways are connected by prostaglandin E2 (PGE2) activation of the aromatase enzy

94 We detected high urinary prostaglandin E2 (PGE2) and ATP levels in Atp6v1b1-/- mi

95 The EP3 receptor is stimulated by prostaglandin E2 (PGE2) and couples to G-proteins of the

96 ing the degradation of inflammation mediator prostaglandin E2 (PGE2) and other prostanoids.

97 nhanced biosynthesis of eicosanoids, such as prostaglandin E2 (PGE2) and PGF2alpha, precedes the onse

98 also measured levels of the PUFA metabolites prostaglandin E2 (PGE2) and resolvins.

99 Prostaglandin E2 (PGE2) and viability were measured with

100 Peritoneal fluid concentrations of prostaglandin E2 (PGE2) are higher in women with endomet

101 We describe an unexpected role for prostaglandin E2 (PGE2) as a negative regulator of retin

102 Here we describe prostaglandin E2 (PGE2) as a regulator of endodermal fat

103 Prostaglandin E2 (PGE2) augments distinct inspiratory mo

104 Here we demonstrate in vivo that prostaglandin E2 (PGE2) can differentially increase the

105 Inflammation-induced release of prostaglandin E2 (PGE2) changes breathing patterns and t

106 Proinflammatory lipid mediators including prostaglandin E2 (PGE2) contribute to the establishment

107 actor A (VEGF-A), interleukin 10 (IL-10) and prostaglandin E2 (PGE2) cooperatively induced FasL expre

108 the cyclooxygenase (COX)-derived eicosanoid prostaglandin E2 (PGE2) drives cirrhosis-associated immu

109 cell activation via producing high level of prostaglandin E2 (PGE2) due to their thousands-fold high

110 The endogenous lipid mediator prostaglandin E2 (PGE2) exerts anti-fibrotic effects, in

111 Recently, prostaglandin E2 (PGE2) exposure, either in vivo or ex v

112 ase (mPGES)-1 is responsible for the massive prostaglandin E2 (PGE2) formation during inflammation.

113 cible enzyme that catalyzes the formation of prostaglandin E2 (PGE2) from prostaglandin H2 (PGH2).

114 Prostaglandin E2 (PGE2) has been reported to play an ess

115 Prostaglandin E2 (PGE2) has been shown to enhance IL-17

116 Prostaglandin E2 (PGE2) has emerged as a principal media

117 The lipid mediator prostaglandin E2 (PGE2) has the capacity to limit fibros

118 ical hyperalgesia and marked prolongation of prostaglandin E2 (PGE2) hyperalgesia, a key feature of h

119 nduction of cyclooxygenase (COX)-2-dependent prostaglandin E2 (PGE2) in human DCs.

120 vestigated the contribution of COX-2-derived prostaglandin E2 (PGE2) in the formation of a premetasta

121 Here we identified prostaglandin E2 (PGE2) in the tumor as a key mediator o

122 induced a large increase in the excretion of prostaglandin E2 (PGE2) in urine, which was suppressed i

123 ntestine with 5-hydroxytryptamine (5-HT) and prostaglandin E2 (PGE2) induced goblet cell exocytosis f

124 we report that the proinflammatory cytokine prostaglandin E2 (PGE2) induces the malignant SN12C, but

125 e ChAT activity, treatment of microglia with prostaglandin E2 (PGE2) inhibited it.

126 Prostaglandin E2 (PGE2) is a key mediator in inflammator

127 ted insulin secretion (GSIS), its metabolite prostaglandin E2 (PGE2) is a known inhibitor.

128 Prostaglandin E2 (PGE2) is a pleiotropic lipid mediator

129 Prostaglandin E2 (PGE2) is a potent lipid mediator that

130 Prostaglandin E2 (PGE2) is an important biological media

131 Here we show that Prostaglandin E2 (PGE2) is an inflammatory cytokine that

132 n strongly linked to adhesion formation, and Prostaglandin E2 (PGE2) is associated with both adhesion

133 Prostaglandin E2 (PGE2) is associated with proliferation

134 Prostaglandin E2 (PGE2) is derived from arachidonic acid

135 ly induced priming is detected not only when prostaglandin E2 (PGE2) is presented to the peripheral n

136 Prostaglandin E2 (PGE2) is regarded as the main mediator

137 Proinflammatory prostaglandin E2 (PGE2) is secreted by many cell types a

138 strated that the immunomodulatory eicosanoid prostaglandin E2 (PGE2) is synergistically increased dur

139 lls with defective PKA regulation, increased prostaglandin E2 (PGE2) led to increased cAMP levels and

140 effect of MSK1/2 knockout was seen on plasma prostaglandin E2 (PGE2) levels following intraperitoneal

141 cholamines induce inflammation by increasing prostaglandin E2 (PGE2) levels in ovarian cancer cells.

142 X-1 and PGIS protein expression and PGI2 and prostaglandin E2 (PGE2) levels in the kidney and renal v

143 Local and systemic interleukin-6 (IL-6) and prostaglandin E2 (PGE2) levels were significantly elevat

144 ted the effects of the inflammatory mediator prostaglandin E2 (PGE2) on colorectal CSC development an

145 ers described a positive regulatory role for prostaglandin E2 (PGE2) on HSC function ex vivo.

146 o-inflammatory effects of macrophage-derived prostaglandin E2 (PGE2) on Th17 cells.

147 Modulating levels of prostaglandin E2 (PGE2) or PGB2 restricted distal segmen

148 Accumulation of COX-2-derived prostaglandin E2 (PGE2) parallels the substantial increa

149 vate, via Tpl2, the cyclooxygenase-2 (Cox-2)-prostaglandin E2 (PGE2) pathway, which we show here to b

150 fibroblast via the cyclooxygenase 2 (COX-2)/prostaglandin E2 (PGE2) pathway.

151 vitalization of the cyclooxygenase (COX) and prostaglandin E2 (PGE2) pathway.

152 We tested the hypothesis that astrocytic prostaglandin E2 (PgE2) plays a key role for cerebrovasc

153 ntent, total antioxidant capacity, effect on prostaglandin E2 (PGE2) production and anticancer cell p

154 f iPSC-MSCs and BM-MSCs were associated with prostaglandin E2 (PGE2) production and cell-cell contact

155 endothelial cells, we demonstrate that local prostaglandin E2 (PGE2) production in deep brain areas,

156 on of cyclooxygenase 2 (COX-2) and resultant prostaglandin E2 (PGE2) production.

157 Activation of EP2 receptors by prostaglandin E2 (PGE2) promotes brain inflammation in n

158 Prostaglandin E2 (PGE2) promotes Th17 expansion while ot

159 ase-2 (COX-2) activity and activation of the prostaglandin E2 (PgE2) receptors EP2 and EP4.

160 py effectively induces apoptosis, associated prostaglandin E2 (PGE2) release paradoxically promotes n

161 ge (0.57-fold Nrf-2 and 0.34-fold HO-1), and prostaglandin E2 (PGE2) release was increased in samples

162 is responsible for arachidonic acid (AA) and prostaglandin E2 (PGE2) release.

163 ypersensitivity was impaired, and subsequent prostaglandin E2 (PGE2) response was blunted.

164 ion of infected apoptotic cells (IACs) drive prostaglandin E2 (PGE2) secretion to generate Th17 cells

165 The pain mediator prostaglandin E2 (PGE2) sensitizes nociceptive pathways

166 e results from LPS-induced the production of prostaglandin E2 (PGE2) show that, esculetin, curcumin a

167 pithelial cell culture system, we found that prostaglandin E2 (PGE2) signaling through one of its rec

168 In human aortic smooth muscle cells, prostaglandin E2 (PGE2) stimulates adenylyl cyclase (AC)

169 Prostaglandin E2 (PGE2) stimulates HSC renewal and engra

170 Platelet-induced COX-2-dependent prostaglandin E2 (PGE2) synthesis in HT29 cells was invo

171 is in mouse neonates through upregulation of prostaglandin E2 (PGE2) synthesis pathway consisting of

172 dothelium followed by COX1-mediated cerebral prostaglandin E2 (PGE2) synthesis.

173 eurological conditions, mainly via producing prostaglandin E2 (PGE2) that activates four membrane rec

174 TLR4 ligand, induces macrophages to generate prostaglandin E2 (PGE2) through inducible COX-2 and micr

175 Fever occurs upon binding of prostaglandin E2 (PGE2) to EP3 receptors in the median p

176 le cyclooxygenase-2 (COX-2) and its mediator prostaglandin E2 (PGE2) to inhibit transforming growth f

177 COX-2 overexpression or Prostaglandin E2 (PGE2) treatment increased beta1-integr

178 We reported previously that prostaglandin E2 (PGE2) up-regulates IL-23 in vitro in b

179 dent manner for their enhanced production of prostaglandin E2 (PGE2) via a calcium-dependent cytosoli

180 significantly increased, while the level of prostaglandin E2 (PGE2) was decreased.

181 In a targeted embryonic chemical screen, prostaglandin E2 (PGE2) was identified as a potential th

182 nsforming growth factor beta (TGF-beta), and prostaglandin E2 (PGE2) were higher in patients with DCL

183 phage inflammatory protein (MIP)-1alpha, and prostaglandin E2 (PGE2) were measured.

184 hanges in the PR pathway on the secretion of prostaglandin E2 (PGE2), a key factor for promoting cell

185 Prostaglandin E2 (PGE2), a potent lipid signaling molecu

186 aim of this study was to analyze the role of prostaglandin E2 (PGE2), a prostaglandin known to be inc

187 lones, with a focus on modulatory effects of prostaglandin E2 (PGE2), and evaluate progeny for p53 mu

188 ls overexpress cyclooxygenase-2, overproduce prostaglandin E2 (PGE2), and exhibit defective intracell

189 Although immunoregulatory factors, such as Prostaglandin E2 (PGE2), and their mechanisms of action

190 looxygenases (COXs) and their final product, prostaglandin E2 (PGE2), are known to play important rol

191 macrophages, resulting in enhanced levels of prostaglandin E2 (PGE2), autocrine activation of the mac

192 s: estradiol-17-beta-glucuronide (E17betaG), prostaglandin E2 (PGE2), cholecystokinin 8 (CCK8), and v

193 vs. patient 0.1 ng/ml) and leukocytes [e.g., prostaglandin E2 (PGE2), control 21.9 +/- 7.4 ng/ml vs.

194 including chemokines, cytokines, COX-2, and prostaglandin E2 (PGE2), in vivo.

195 scued by the addition of arachidonic acid or prostaglandin E2 (PGE2), indicating a phospholipase-depe

196 a-intercalated cells, via release of ATP and prostaglandin E2 (PGE2), influence the activity of trans

197 valuate levels of four major labor triggers, prostaglandin E2 (PGE2), interleukin (IL)-1beta, IL-6, a

198 Prostaglandins, particularly prostaglandin E2 (PGE2), play an important role during i

199 rs, such as vasoactive intestinal peptide or prostaglandin E2 (PGE2), regulate intestinal anion/fluid

200 Previously, we revealed that prostaglandin E2 (PGE2), released during hypercapnic cha

201 at the key products of NOS2 and COX2, NO and prostaglandin E2 (PGE2), respectively, promote feed-forw

202 ed autologous T cells in a manner relying up prostaglandin E2 (PGE2), STAT-3, and superoxide.

203 this enzyme, the proinflammatory eicosanoid prostaglandin E2 (PGE2), stimulates adipose tissue aroma

204 al cells with M27 increases the secretion of prostaglandin E2 (PGE2), the enzymatic product of Ptges,

205 nd were treated with vehicle, diclofenac, or prostaglandin E2 (PGE2), the most important COX-2 produc

206 We observed that prostaglandin E2 (PGE2), through its receptor EP4, is do

207 Cyclooxygenase-2 (COX-2) and its metabolite prostaglandin E2 (PGE2), two pivotal proinflammatory/onc

208 ce the synthesis of the small lipid mediator prostaglandin E2 (PGE2), which alters the host T cell re

209 ry enzyme responsible for the degradation of prostaglandin E2 (PGE2), which is known to promote tumor

210 Prostaglandin E2 (PGE2), which stimulates HSPC survival

211 similar to that of intraplantar injection of prostaglandin E2 (PGE2), which was significantly attenua

212 gene-7 (MIG-7) protein as critical for COX-2/prostaglandin E2 (PGE2)- and Akt/GSK-3beta-dependent tum

213 volves calcium efflux and stimulation of the prostaglandin E2 (PGE2)-cyclic adenosine monophosphate (

214 ted macrophages and expressed high levels of prostaglandin E2 (PGE2)-forming enzymes microsomal PGE2

215 saccharide-, parathyroid hormone (PTH)-, and prostaglandin E2 (PGE2)-induced expression of MMP-13 in

216 al of this study was to functionally compare prostaglandin E2 (PGE2)-sensitive receptors in human pri

217 Combination of polyamine and prostaglandin E2 (PGE2)-synthesis inhibitors reduced the

218 levels of sphingosine-1-phosphate, CCL20 and prostaglandin E2 (PGE2).

219 ound-inflammation-induced trophic signals is prostaglandin E2 (PGE2).

220 involving reactive oxygen species (ROS) and prostaglandin E2 (PGE2).

221 f cyclooxygenase-2 (COX-2) and production of prostaglandin E2 (PGE2).

222 result of elevated levels of COX-2-dependent prostaglandin E2 (PGE2).

223 IL-8 pathway by increasing the production of prostaglandin E2 (PGE2).

224 tion of living cell growth involves secreted prostaglandin E2 (PGE2).

225 iety of lipid signaling molecules, including prostaglandin E2 (PGE2).

226 tor, glycolipid alpha-GalCer, and endogenous prostaglandin E2 (PGE2).

227 ciated with production of the lipid mediator prostaglandin E2 (PGE2).

228 lective antagonist and imitated by exogenous prostaglandin E2 (PGE2).

229 ted by indoleamine 2,3-dioxygenase (IDO) and prostaglandin E2 (PGE2).

230 roduction of the antifibrotic lipid mediator prostaglandin E2 (PGE2).

231 -2) pathway and the concomitant increases in prostaglandin E2 (PGE2).

232 2 (cyclooxygenase-2) and increases levels of prostaglandin E2 (PGE2).

233 nhancing ability of a short-term exposure of prostaglandin E2 (PGE2); this strategy has now progresse

234 as it converts 2-AG to the glycerol ester of prostaglandin E2 (PGE2-G).

235 Here we report that signaling through the prostaglandin-E2 (PGE2) EP4 receptor potently suppresses

236 protocol with bone morphogenetic protein 4, prostaglandin-E2 (PGE2), and StemRegenin 1 (SR1) for hem

237 Thus, the glyceryl ester of prostaglandin E2, PGE2-G, mobilizes Ca(2+) and activates

238 synaptic inhibition occur partially through prostaglandin E2- (PGE2-) and PKA-dependent phosphorylat

239 Prostaglandin E2, platelet-derived growth factor (PDGF)

240 njunctiva (CNJ) of the mice was cultured for prostaglandin E2 production induced by sPLA2-IIa with va

241 e, gedunin (10 microM) inhibited LPS-induced prostaglandin E2 production, cyclooxygenase-2 expression

242 LPS-stimulated prostaglandin-E2 production was dysregulated in macropha

243 tion and lipid deposition, and to controlled prostaglandin-E2 production.

244 Prostaglandin E2 promotes cancer invasion, and in a feed

245 Prostaglandin E2 promotes not only immune tolerance and

246 Plasma levels of histamine, leukotriene B4, prostaglandin E2, prostaglandin F2, pH, and HCO3 were me

247 essenger RNA expression of cyclooxygenase-2, prostaglandin E2, prostanoid receptor-1, tumour necrosis

248 ked whether cyclooxygenase-2, its derivative prostaglandin E2, prostanoid receptors and pro-inflammat

249 sphatidylcholine, lysophosphatidic acid, and prostaglandin E2) recapitulated M1 phenotype in iPLA2bet

250 Activation of prostaglandin E2 receptor (PGE(2)) subtype EP2 promotes

251 els of acquired AI resistance indicated that prostaglandin E2 receptor 4 (PTGER4) is upregulated afte

252 of noscapine in HLFs were blocked by the EP2 prostaglandin E2 receptor antagonist, PF-04418948, but n

253 Further, mice lacking the prostaglandin E2 receptor EP3 selectively on serotonergi

254 The prostaglandin E2 receptor family consists of four subtyp

255 Primary mouse microglia that lack prostaglandin E2 receptor subtype 2 (EP2) show decreased

256 nd first intron of the PTGER4 gene (encoding prostaglandin E2 receptor subtype 4; all P < 5 x 10(-5))

257 ed a potent and selective antagonist for the prostaglandin E2 receptor subtype EP2, TG6-10-1, with a

258 el mechanism of noscapine action through EP2 prostaglandin E2 receptor-mediated activation of PKA in

259 n D2 receptors (DPs) DP1 (49) and DP2 (558), prostaglandin E2 receptors (EPs) EP1 (266) and EP4 (117)

260 resistance protein 4, and G-protein-coupled prostaglandin E2 receptors 1 and 2), abolished P-glycopr

261 Increased cyclooxygenase-2 expression and prostaglandin E2 release could be abrogated in metastati

262 oxyprostaglandin dehydrogenase, resulting in prostaglandin E2 release in human breast cancer.

263 s activators of PKA, including adenosine and prostaglandin E2, results in a profound delay of neutrop

264 ated cyclooxygenase-2 (COX-2) expression and prostaglandin E2 secretion, indicating a proinflammatory

265 Additionally, PGDH knockdown affected prostaglandin E2 signaling as measured by cAMP generatio

266 g components in the cyclooxygenase-2 (COX-2)/prostaglandin E2 signaling cascade (phospholipase A2, CO

267 a mechanism involving caspase activation and prostaglandin E2 signaling.

268 Immunity, Coulombe et al. (2014) report that prostaglandin E2 suppresses innate and adaptive immune r

269 e been extensively investigated, identifying prostaglandin E2 synthase (mPGES)-1 and 5-lipoxygenase (

270 Microsomal prostaglandin E2 synthase (mPGES)-1 is responsible for t

271 S) 2, and fibronectin expression by HLFs and prostaglandin E2 synthase (PGE2S) expression by AECs wer

272 e were a coding variant in the gene encoding prostaglandin E2 synthase (PTGES2; P = 9.3 x 10(-5)) res

273 Microsomal prostaglandin E2 synthase type 1 (mPGES-1) is responsibl

274 Dual inhibition of microsomal prostaglandin E2 synthase-1 (mPGES-1) and 5-lipoxygenase

275 also been linked to asthma, where deficient prostaglandin E2 synthesis has been associated with airw

276 The febrile response is triggered by prostaglandin E2 synthesis mediated by induced expressio

277 lic phospholipase A2, which was reflected in prostaglandin E2 synthesis.

278 into the role played by genetic variation in prostaglandin E2 synthetic and signaling pathways in PGD

279 sion induced by inflammatory pain depends on prostaglandin E2 that is synthesized by cyclooxygenase 2

280 t of diffusible signaling molecules, such as prostaglandin E2 The capability of human or murine CAFs

281 erinatal lethal with reduced brain levels of prostaglandin E2 The non-functional phospholipase A2-act

282 reversed hyperalgesia induced by intrathecal prostaglandin E2 To distinguish between a peripheral/spi

283 KSHV utilizes inflammatory cyclooxygenase 2/prostaglandin E2 to establish and maintain latency.

284 The whipworm (Trichuris suis) secretes prostaglandin E2 to suppress proinflammatory properties

285 le formation similar to that observed during prostaglandin E2 treatment.

286 We propose that tick salivary prostaglandin E2 triggers antibody class switching in ma

287 r the formation of the potent lipid mediator prostaglandin E2 under proinflammatory conditions, and t

288 rometry revealed the very specific nature of prostaglandin E2 up-regulation as the other analyzed AA

289 We also evaluated prostaglandin E2 urinary metabolite (PGE-M) in an indepe

290 Cyclooxygenase and lipoxygenase metabolites prostaglandin E2 (vasodilator) and 12-hydroxyeicosatetra

291 eukin-6, chemokine (C-C motif) ligand 5, and prostaglandin E2 was assessed by enzyme-linked immunosor

292 By contrast, the induction of ID1 by prostaglandin E2 was mediated by cAMP response element-b

293 However, responses to prostaglandin E2 were decreased by CS exposure.

294 ls pulsed in vitro for 2 hours with dimethyl prostaglandin E2 were functionally similar to those from

295 e metabolites 11-hydroxyeicosatetraenoic and prostaglandin E2 were reduced by 80% to 90% in septic pa

296 ecursor self-renewal also was obtained using prostaglandin E2, which is downstream of cyclooxygenase

297 Prostaglandin E2, which is known to contribute to cancer

298 DUSP2 led to overproduction of COX-2-derived prostaglandin E2, which promoted cancer stemness via the

299 ocompetent host requires their production of prostaglandin E2, which suppresses immunity and fuels tu

300 induced increase in hippocampal and thalamic prostaglandin E2, while the COX-2-specific inhibitor NS-